Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 8/20 | 0.53 |
| ▸ | PARP15 | Q460N3 | 7/20 | 0.53 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.53 |
| ▸ | ACACB | O00763 | 4/20 | 0.45 |
| ▸ | ACACA | Q13085 | 2/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.45 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1390989 | 0.88 | PARP10 (0.53) | PARP10PARP15PARP2NR1H4SCN9A | |
| SCHEMBL4014416 | 0.87 | PARP10 (0.43) | PARP10PARP15PARP2ACACBFFAR1 | |
| SCHEMBL1854146 | 0.85 | PARP10 (0.51) | PARP10PARP15PARP2ACACBACACA | |
| SCHEMBL7963743 | 0.84 | ALDH1A1 (0.53) | — | |
| SCHEMBL7963745 | 0.84 | ALDH1A1 (0.53) | — | |
| SCHEMBL7963747 | 0.84 | ALDH1A1 (0.53) | — | |
| SCHEMBL3428815 | 0.84 | PARP10 (0.49) | PARP10PARP15PARP2ACACBACACA | |
| SCHEMBL27823231 | 0.83 | PARP10 (0.40) | PARP10PARP15PARP2ACACBFFAR1 | |
| SCHEMBL3325497 | 0.82 | GPR119 (0.52) | — | |
| SCHEMBL716744 | 0.82 | MAOB (0.55) | PARP10PARP15PARP2ACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445501-B2 | Substituted 7-carboxamido-pyrrolo[3,2-d]pyrimidines | TAKEDA GMBH (DE) | 2013-05-21 | — | — | US | disclosed |
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| EP-2247594-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | Nycomed GmbH (DE) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009106531-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | PDE5A, PDE3A, PDE2A | PARP10 1059/4885PARP15 227/4885PARP2 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.